Fort Sheridan Advisors LLC Acquires 1,730 Shares of Pfizer Inc. (NYSE:PFE)

Fort Sheridan Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 78,522 shares of the biopharmaceutical company’s stock after acquiring an additional 1,730 shares during the period. Pfizer makes up approximately 1.3% of Fort Sheridan Advisors LLC’s investment portfolio, making the stock its 13th largest holding. Fort Sheridan Advisors LLC’s holdings in Pfizer were worth $4,637,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Capital World Investors lifted its holdings in Pfizer by 0.5% during the third quarter. Capital World Investors now owns 241,360,858 shares of the biopharmaceutical company’s stock worth $10,381,066,000 after acquiring an additional 1,171,443 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Pfizer by 3.3% during the third quarter. Geode Capital Management LLC now owns 99,593,093 shares of the biopharmaceutical company’s stock worth $4,272,514,000 after acquiring an additional 3,211,904 shares in the last quarter. Morgan Stanley lifted its holdings in Pfizer by 3.4% during the second quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company’s stock worth $1,875,532,000 after acquiring an additional 1,582,052 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Pfizer by 28.8% during the third quarter. Franklin Resources Inc. now owns 45,980,291 shares of the biopharmaceutical company’s stock worth $1,977,614,000 after acquiring an additional 10,270,562 shares in the last quarter. Finally, UBS Asset Management Americas Inc. lifted its holdings in shares of Pfizer by 2.0% in the third quarter. UBS Asset Management Americas Inc. now owns 23,728,801 shares of the biopharmaceutical company’s stock valued at $1,020,576,000 after purchasing an additional 457,513 shares in the last quarter. Hedge funds and other institutional investors own 66.50% of the company’s stock.

NYSE PFE traded down $0.47 during trading on Friday, reaching $49.92. 22,423,685 shares of the company’s stock were exchanged, compared to its average volume of 24,886,970. The business has a 50 day moving average price of $51.27 and a 200-day moving average price of $51.84. The stock has a market capitalization of $281.94 billion, a P/E ratio of 11.45, a PEG ratio of 0.59 and a beta of 0.76. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.40 and a quick ratio of 1.19. Pfizer Inc. has a fifty-two week low of $38.47 and a fifty-two week high of $61.71.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.80 by ($0.18). Pfizer had a return on equity of 39.33% and a net margin of 26.97%. The firm had revenue of $25.66 billion for the quarter, compared to the consensus estimate of $24.73 billion. During the same quarter in the prior year, the firm earned $0.93 EPS. The company’s revenue was up 76.8% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post 6.69 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Friday, May 13th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date of this dividend is Thursday, May 12th. Pfizer’s dividend payout ratio is presently 36.70%.

A number of brokerages have recently commented on PFE. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a report on Tuesday, May 3rd. Berenberg Bank set a $50.00 price target on Pfizer in a report on Thursday, April 21st. BMO Capital Markets boosted their price target on Pfizer from $60.00 to $76.00 in a report on Friday, January 14th. The Goldman Sachs Group set a $51.00 price target on Pfizer in a report on Wednesday, May 4th. Finally, Wells Fargo & Company lowered their target price on Pfizer from $60.00 to $55.00 in a research report on Wednesday, May 4th. Eleven research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $57.05.

In other news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the business’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the sale, the executive vice president now owns 38,146 shares in the company, valued at $1,907,300. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.05% of the company’s stock.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More